Phase II Front-Line Pancreatic Cancer Clinical Trial

Gemcitabine with or without bavituximab as front-line therapy in advanced pancreatic cancer

Enrollment is open in a Phase II clinical trial to evaluate bavituximab combined with gemcitabine in patients with previously untreated stage IV pancreatic cancer. The multi-center, randomized open-label trial will enroll up to 70 patients in the United States.

Primary Endpoint Median Overal Survival (OS)
Secondary Endpoints Overall response rate (ORR), duration of response (DR), and progression-free survival (PFS)

For additional information and a list of clinical sites open for enrollment, please visit the ClinicalTrials.gov page for this trial

Phase I/II Hepatocellular Carcinoma (HCC) Clinical Trial

Bavituximab and Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Enrollment is open in a Phase I/II open-label trial to evaluate bavituximab and sorafenib in patients with advanced HCC. The open-label trial will enroll up to 50 patients in the United States.

Primary Endpoint Maximum tolerated dose (MTD), time to progression (TTP)
Secondary Endpoints Response rate (ORR), progression free-survival (PFS), overall survival (OS), safety and tolerability

For additional information and a list of clinical sites open for enrollment, please visit the ClinicalTrials.gov page for this trial

Phase I/II Second-Line Castration Resistant Prostate Cancer (CRPC) Clinical Trial

Bavituximab with cabazitaxel in second-line castration resistant prostate cancer (CRPC)

Enrollment is open in a Phase I/II clinical trial to evaluate bavituximab (PS-targeting monoclonal antibody) combined with cabazitaxel as second-line experimental treatment in patients with CRPC. The single-arm open-label trial will enroll up to 31 patients at multiple locations in the United States.

Primary Endpoint Progression-free survival (PFS) frequency after 12 weeks
Secondary Endpoints PSA response rate, objective response rate (ORR) by RECIST for patients with measurable disease, overall survival, and safety parameters

For additional information and a list of clinical sites open for enrollment, please visit the ClinicalTrials.gov page for this trial

Phase I HER2-Negative Metastatic Breast Cancer Clinical Trial

Bavituximab with Paclitaxel in HER2-Negative Metastatic Breast Cancer

Enrollment is open in a Phase I clinical trial to evaluate bavituximab combined with paclitaxel in patients with HER2-negative metastatic breast cancer. The single-arm open-label trial will enroll up to 14 patients.

Primary Endpoint Safety, feasibility, and tolerability of combining paclitaxel with weekly bavituximab therapy
Secondary Endpoints Pharmacodynamics, coagulation marker changes, overall response rate (ORR) and progression free survival (PFS)

For additional information and a list of clinical sites open for enrollment, please visit the ClinicalTrials.gov page for this trial

Phase Ib Front-Line Non-Small Cell Lung Cancer (NSCLC) Clinical Trial

Bavituximab with Pemetrexed and Carboplatin in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Enrollment is open in a Phase I clinical trial to evaluate bavituximab (PS-targeting monoclonal antibody) combined with pemetrexed and carboplatin in patients with locally advanced or metastatic NSCLC. The open-label dose escalation trial will enroll up to 25 patients.

Primary Endpoints Safety, dose-limiting toxicity (DLT) and recommended Phase II dose of bavituximab in combination with carboplatin and pemetrexed in advanced non-squamous NSCLC
Secondary Endpoints Overall response rate (ORR) measured by RECIST criteria, progression-free survival (PFS) and overall survival (OS) and exploratory biomarkers

For additional information and a list of clinical sites open for enrollment, please visit the ClinicalTrials.gov page for this trial

If you are a health care provider interested in referring a patient or learning more about our ongoing clinical trials, please visit www.peregrinetrials.com, or send an e-mail to Peregrine Pharmaceuticals at This e-mail address is being protected from spambots. You need JavaScript enabled to view it

If you are a patient interested in participating in one of our trials, please have your personal physician send an email correspondence to Peregrine.